Research Highlights: September 2026

Prepared from the September 10, 2026 SIO Research Committee meeting discussion. These summaries reflect the committee’s interpretation of the source material and are intended to be hypothesis-generating and educational, not clinical recommendations.

Monthly Research Digest Paper Highlight

TCM Directional Drug Penetration Therapy Speeds GI Recovery After Ovarian Cancer Surgery — But Questions Remain

Wu X, Wang W. Effects of traditional Chinese medicine directional drug penetration therapy on gastrointestinal function, gut microbiota, and sleep quality in postoperative ovarian cancer patients: a randomized controlled trial. Supportive Care in Cancer. 2026;34(9):874. doi:10.1007/s00520-026-11096-w. PMID: 42616157.

Each month, the SIO Research Committee reviews recently published papers voted on by our members and selects one for in-depth discussion. This month’s discussion paper was selected from 11 nominated articles, with 14 of our committee members participating in the vote.

What they did: In a single-center RCT of 112 post-operative ovarian cancer patients (56 per arm), all patients received standard post-operative rehabilitation (fluid/electrolyte management, nutrition support, anti-inflammatory therapy, and rehab exercise). The intervention arm additionally received a TCM “directional drug penetration therapy” — a device that uses electroporation, medium-frequency pulses, and thermal effects to drive an herbal formula (raw rhubarb, peach seed, clove, costus root, red peony root) transdermally at the ST36 (Zusanli) acupoint, bypassing hepatic first-pass metabolism, continued until the patient’s first bowel movement.

What they found:

• Faster GI recovery: Significantly shorter time to first bowel sounds, first flatus, and first defecation in the intervention group (p<0.05).
• Gut microbiota shifts: No change in overall microbial diversity, but enrichment of short-chain fatty acid–producing bacteria in the intervention group, versus dominance of Gardnerella in controls.
• Better sleep: The therapy attenuated the typical post-operative decline in sleep quality (measured by the Pittsburgh Sleep Quality Index).

Why the committee found it interesting: This is a genuinely novel intervention — there is very little existing literature combining electroporation-assisted transdermal herbal delivery with an acupuncture point in the post-surgical setting. The physiologic outcomes measured (bowel sounds, flatus, defecation) are less prone to placebo/expectancy effects than patient-reported measures, and the intervention was layered on top of an already-strong standard-of-care rehabilitation protocol — meaning the observed benefit is additive to good usual care, not a replacement for it. No adverse events were reported.

Where the committee urges caution: The trial was not blinded and had no sham/placebo control arm, and lacked prospective trial registration. The microbiome findings, while intriguing, come from a small sample size for that type of analysis and did not clearly account for confounders like diet, antibiotic use, or lifestyle — the committee views the mechanistic microbiome story as hypothesis-generating rather than established. A related 2026 scoping review rated standardized acupuncture as moderate-certainty for improving bowel recovery time, but rated herbal/external TCM therapies as low-certainty — suggesting the acupuncture/electrical stimulation component, rather than the herbal formula itself, may be doing most of the work.

Bottom line: An interesting, low-risk, non-pharmacologic approach with a promising early signal for accelerating GI recovery and improving sleep after ovarian cancer surgery. Larger, blinded, sham-controlled trials are needed before this can be considered practice-changing.

This summary reflects the SIO Research Committee’s interpretation of the published findings and is intended to stimulate discussion, not to serve as clinical guidance.

Here are the two honorable-mention articles from this month’s vote, not selected for full discussion but noted by the committee:

Effects of motivational music on sleep quality for caregivers of patients with advanced cancer: a randomized controlled trial. Valero-Cantero I, Vázquez-Sánchez MÁ, Espinar-Toledo M, Corral-Pérez J, Casals-Sánchez JL, Casals C. Supportive Care in Cancer. 2026;34(8):824. doi:10.1007/s00520-026-11038-6.

Acupuncture for Taxane-induced Peripheral Neuropathy: A Randomized Controlled Trial. Ohno S, Inokuchi H, Kasuya D, Takahashi T, Yamaguchi S. Anticancer Research. 2026;46(8):4745-4753. doi:10.21873/anticanres.18331.

ASCO 2026 Highlights

Summarized for the committee by Ana Maria Lopez, MD.

1. Be Well Study: Lifestyle Intervention Improves Quality of Life in Patients with Elevated BMI

A randomized trial comparing a 24-month lifestyle-based intervention to health education alone in cancer patients/survivors with elevated BMI. Interim quality-of-life data show the lifestyle intervention arm had greater improvements in physical function, global physical and mental health, and fatigue compared with education alone. The study’s primary cancer-incidence endpoint data are still maturing and were not yet presented. This adds to a growing body of evidence supporting structured lifestyle intervention over education alone.

2. Yoga Improves Mood, Anxiety, and Fatigue in Cancer Survivors

A well-designed Phase 3 RCT of a yoga program (incorporating movement, meditation, and breathing exercises) in survivors without metastatic disease. Compared with standard care, participants in the yoga arm reported significantly less mood disturbance, anxiety, and fatigue. (The study’s primary endpoint was sleep quality; these results reflect secondary outcomes.) The field’s next step, per committee discussion, is comparative-effectiveness research — testing mind-body therapies against one another and against other interventions like aerobic exercise, rather than against usual care alone.

3. Short-Term Fasting May Enhance Chemotherapy Response in Ovarian Cancer

A small prospective pilot RCT (18 patients per arm) in women receiving neoadjuvant chemotherapy for ovarian carcinoma, randomized to short-term fasting (approx. 350 kcal/day of water, herbal tea, vegetable juice, and broth, from 36 hours before to 24 hours after each chemotherapy cycle) versus a free diet. After three cycles, the fasting group showed a significant reduction in insulin levels, and patients in the fasting group who went on to surgery had a greater treatment response. Though small and not yet published as a full manuscript, this builds on prior work (Longo, Safdie) suggesting fasting around chemotherapy cycles may reduce toxicity, and warrants larger confirmatory studies.

4. GLP-1 Receptor Agonists and Cancer Risk: Two Signals Worth Watching

Two retrospective analyses (abstract form) suggest a potential protective association between GLP-1 receptor agonist / gliptin use and cancer outcomes:

• In a global study spanning seven solid tumor types (breast, prostate, lung, colorectal, liver, kidney, pancreas), GLP-1/gliptin use was associated with fewer stage 4 diagnoses for lung, breast, colorectal, and liver cancers.
• In patients with inflammatory bowel disease (Crohn’s or ulcerative colitis) — a population at elevated colorectal cancer risk — GLP-1 use was associated with a significantly reduced incidence of colorectal cancer, including among patients with comorbid diabetes.

Both findings are retrospective and hypothesis-generating; prospective studies are needed. An open question remains around melanoma risk with GLP-1 inhibitors (current evidence suggests no increased risk, but this is not yet fully settled), and animal data have raised a signal for potential thyroid cancer risk — both areas the committee will continue to watch.

Compiled by the SIO Research Committee. Questions or comments may be directed to the committee co-chairs.